Generating evidence for racial and ethnic minorities during development of oncologic therapeutics - Regulatory Focus
Discussions regarding diversity, equity, and inclusion in healthcare and clinical research have been ongoing for decades. However, the COVID-19 global pandemic brought about a new focus on this issue. As the pharmaceutical industry began strategizing on how to improve diversity in its clinical trials, the Reagan-Udall Foundation for the FDA in collaboration with the US Food and Drug Administration’s (FDA’s) Oncology Center of Excellence convened a series of interviews meetings with the industry to discuss the value of diverse representation in clinical trials, the opportunities for driving change, and any challenges in developing and implementing a diversity strategy for oncology clinical trials.